List of Antibodies Companies in Washington - 38

A-Alpha Bio is a biotechnology company harnessing synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. Our experimental platform, AlphaSeq, enables the rapid and quantitative measurement of millions of protein-protein binding affinities simultaneously. Our computational platform, AlphaBind, is trained on the world’s largest protein-protein interaction database and predicts binding strength from sequence. A-Alpha Bio leverages AlphaSeq and AlphaBind for in-house therapeutic programs and in partnership with leading pharmaceutical companies to inform the discovery and development of novel therapeutics. A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington's Institute for Protein Design and Center for Synthetic Biology. To learn more, please visit: https://www.aalphabio.com/

Abacus Bioscience is developing a new class of immunotherapy that unleashes the power of a novel CD180 platform technology. Our Antigen-Specific Immune Accelerants (ASIA) are POTENT, SPECIFIC and DURABLE, with broad applications across infectious disease and oncology.

Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to learn, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Our vision is to deliver breakthrough therapeutics at the click of a button, for everyone.

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test; and Amgen to develop a therapeutic to prevent or treat COVID-19. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has a translational collaboration with AstraZeneca to investigate the use of immunoSEQ T-MAP. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.

Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. We leverage the innovative ADAPTIR™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. Based in Seattle, Washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platform technology. As a result, Aptevo has been able to attract some of the most innovative minds in the field. Many of our team members have notable experience with other pioneering biotech companies including Trubion, ZymoGenetics, Immunex, Dendreon, and VLST.

Arbele is a locally grown pharmaceutical biotech focused on immunotherapy of cancers, immune disorders and neurological diseases. The company founding team has a strong combination of business development and pharmaceutical R&D, with an accumulation of >30 year experience in multinational drug companies. Our motto is to excel patient healthcare through innovation and breakthrough. Our mission is to deliver innovative and cost-effective therapeutics to treat diseases of unmet needs. We focus on antibody-based therapeutic platforms, including chimeric antigen receptor (CAR)-T and Bi-specific antibody technology, while leveraging new technology on CRISPR genome editing. Our culture ingredients are “integrity and social values”.

Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease. We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specificity of antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines.

Research & Diagnostic Products. Bio-Rad is partnering with Biodesix on a test for SARS-CoV-2.EUA (05/2020) for a digital PCR molecular diagnostic test for SARS-CoV-2, the virus that causes coronavirus disease COVID-19. The 2019-nCoV CDC ddPCR Triplex Probe Assay is now authorized for use on the firm's QX200 and QXDx Droplet Digital PCR systems.

Blue Heron has been collaborating with some of the most brilliant minds in the industry to create millions of complex genes using our proprietary GeneMaker® multi-technology platform. We are the first gene synthesis company founded and solely operated in the USA. Our only location in Bothell, Washington subjects us to strict U.S. standards for Intellectual Property (IP) Policy and ensures every contract for each customer is confidential. Because of our simple flat rate pricing, we deliver what no other company can provide — the assurance your project will proceed as quoted. Utilizing high grade reagents and proprietary technology we produce DNA of the utmost quality. Our aptitude for projects involving unusually long or difficult sequences allows clients to eliminate errors, risk, and costs that are simply no longer a necessary part of the research process. Blue Heron Provides: - Dedicated Customer Service - Simple Pricing - Easy Ordering - Strict Client Confidentiality - Guaranteed Turnaround Time - Sequence Design - Synthesis of Genes up to 50KB - Complex Genes (hairpins, repeats) - 100+ IP free Expression Vectors - Free Codon Optimization - Free Archiving Publications Citing Blue Heron Biotech Gene Synthesis: http://www.blueheronbio.com/assets/documents/citations/BlueHeronBiotechCitations.pdf

Bonum Therapeutics is focused on a proven technology that utilizes allosteric regulation to create targeted, highly active, and less toxic medicines.

Chondrex, Inc. has been shaping the landscape of arthritis and inflammation research worldwide since 1996. Chondrex was initially focused on providing scientists with the tools necessary to study the pathogenesis of Rheumatoid Arthritis (RA) as well as to develop and screen potential therapeutics for RA. Over the past 20 years however, our scope has expanded beyond just RA research. We now offer a plethora of products ranging from collagen and monoclonal antibody reagents to a wide variety of assay kits for use in allergy, arthritis, connective tissue, and nephritis related research. One such product line, the Collagen Antibody-Induced Arthritis (CAIA) cocktails, allows for faster and more consistent dosage dependent induction of arthritis in mice than the Collagen Induced Arthritis (CIA) model. Furthermore, the CAIA model can be induced in almost all strains of mice, (including CIA-resistant, T-cell deficient, gene knockout, and transgenic mice) whereas the CIA model requires a restricted haplotype. Chondrex is committed to providing the highest quality and most reliable products in order to accelerate the rate of discovery in arthritis and inflammation research.

CisThera Inc. is a privately owned biopharmaceutical company in the Seattle area. CisThera’s mission is to develop innovative therapeutics to treat cancer, autoimmune diseases, as well as chronic kidney and liver diseases. CisThera is taking a novel approach to identify drugs with greater efficacy that broadly inhibit validated contributors to disease pathogenesis.

Compliment Corporationis a start-up biotechnology company developing revolutionary therapeutics in oncology. Ourmission is to improve cancer treatment by dramatically increasing the effectiveness of cancer drugs and by reducing the toxicities associated with standard chemotherapy treatment.

Tianjin Conjustar Biotechnology Co., Ltd. is a researcher and developer of peptide-drug conjugate intended for oncology treatments. The company was established in early 2022 and is located in Tianjin Airport Free Trade Zone. It was founded by Fosun Health Capital and focuses on cooperative development and independent research.

CytoDyn Inc., a late-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies to treat human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb extension study for HIV as monotherapy, rollover study for HIV as a combination therapy, Phase IIb/III investigative trial for HIV, Phase Ib/II trial for triple-negative breast cancer, and Phase II trial for graft-versus-host disease. CytoDyn Inc. has strategic agreement with Samsung BioLogics Co. Ltd. for the clinical and commercial manufacturing of leronlimab. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Eliem Therapeutics, Inc. is a clinical stage biotechnology company focused on developing therapies for neuronal excitability disorders with the goal of restoring balance in both the peripheral and central nervous systems to help patients live on their own terms. Eliem channels its experience, energy, and passion for improving patients’ quality of life by developing life-changing novel therapies for disorders such as chronic pain, depression, epilepsy, focal onset seizures, and anxiety – conditions that make simple daily activities challenging for impacted patients.

Multivalent RNAi Platform, Delivery

Immusoft is a cell therapy company focused on developing novel therapies for rare diseases using sustained delivery of therapeutic proteins from a patient’s own cells. The company is developing a technology platform called Immune System Programming (ISP™), which modifies a patient’s B cells and instructs them to produce gene-encoded medicines. The B cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients and provide therapeutic benefit for many years. The company is based in Seattle, WA.

InduPro is a biotechnology company that brings proteins on the cell surface closer together, manipulating their interactions and opening new possibilities for treating various conditions.

Just – Evotec Biologics, wholly owned by Evotec SE, is a first-to-industry biologics platform that leverages AI/ML technologies and world-leading molecular design, cell line development, process intensification and continuous manufacturing strategies to advance biotherapeutics from discovery through clinical stages to commercial launch. The Just – Evotec Biologics team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics. Our focus is to accelerate and expand access to biotherapeutics through scientific and technological innovation for our proprietary projects and on behalf of our partners.

Kent Laboratories is a biotech manufacturer located in Bellingham, WA. They specialize in in vitro diagnostics and the production of polyclonal antibodies.

Kineta is a clinical stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives.

Link selects validated cancer targets and novel target combinations to build on existing knowledge in creating better molecules. Our strength as a leadership team comes from decades of previous experience and collaboration in both academic and industry environments. At Link, we know that our goal is elusive and that the work we do is not easy, but we are focused and determined to create better therapeutics. We are not alone. Our mission is supported by an outstanding Board of Directors and collaboration with industry-leading partners.

In 2022, we became part of Absolute Biotech, a new company that unites multiple life science brands into one organization specializing in antibody reagents and services. Learn more at absolutebiotech.com. The extensive LSBio reagent catalog contains over 750,000 products, including 500,000 monoclonal and polyclonal antibodies, 50,000 immunoassays and kits, recombinant proteins, biochemicals, and cell lysates that it sells directly and through a network of international distributors. With over 20 years of expertise in antibody production, validation and immunohistochemistry (IHC), LSBio is a world leader in the antibody industry. LSBio is committed to offering unparalleled customer service and the highest quality reagents to assist our customers in accelerating their research.

Lumen Bio is a clinical-stage biotechnology company developing topically and mucosally delivered biologic drugs to treat and prevent highly prevalent diseases.

Mozart is developing disease-modifying therapies for autoimmune and inflammatory diseases that work by targeting a novel regulatory immune pathway.

Myosana Therapeutics, Inc. is leading the efforts in developing new gene therapies that will slow skeletal muscle degeneration and heart failure.

Olympic Protein Technologies is a contract research organization focused on providing high quality protein science services for clients and partners. The quality of proteins are vital to the success of experiments that form the foundation of the discovery and development of therapeutics. Our staff has a wealth of collective experience in top-tier biotechnology companies successfully designing, producing and characterizing protein therapeutic candidates as well as critically important antigens and reagents. This experience includes solving problems associated with the expression/purification of challenging proteins. The aim of our team is to leverage this knowledge to provide the best experience and outcomes for our partners and clients by providing quality science delivered with full engagement and the highest standards, integrity, and data security. We currently offer construct design, expression, protein production & characterization, biomolecular interaction analysis, antibody generation, and protein engineering services. We also can leverage our network of protein science contacts to provide access to other types of analyses, such as advanced biophysical technologies, for your project. As we grow we will build on our existing capabilities while broadening our offerings to include other protein science services. We are located in Seattle Washington USA.

Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.

OncoResponse is an immuno-oncology biotech company that is leveraging its proprietary human antibody platform to discover novel targets and identify fully human monoclonal antibodies as therapeutics for the treatment of cancers. It identifies genuine human antibodies to a variety of high-value targets linked with immunosuppressive myeloid biology.OncoResponse's antibody pipeline is expected to alleviate TME immunosuppression and boost immune activation, turning cold tumors hot.

Proteios Technology is a spin-out from the University of Washington developing a flexible protein technology platform. Proteios’ protein technology is based on a patented dodecapeptide (affinity tag) that exhibits micromolar affinity for silica substrates and eluded using low-cost, biologically-safe reagents. When incorporated to either the N- or C-terminus of a protein, the tag provides a convenient handle for automated protein manipulations, including protein/biopharmaceutical purification, cell enrichment/depletion for cellular therapies, microtiter-based high-throughput (parallel) protein purification, printing protein or antibody chips for HTS, immobilized biocatalysis, and biosensors. Proteios is initially focused on providing easy-to-use, affordable and rapid kits to purify recombinant proteins, where we have a competitive advantage in cost (5x-10x less expensive), throughput (12x improvement), quality (50% improvement in failure rate), purity (> 90%), yield (> 15 mg), and safety (absence of heavy-metal impurities by using biologically-safe reagents).

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. On Dec. 14, 2023, Pfizer completed the acquisition of Seagen.

SISCAPA technology is the smart shortcut to sensitive quantitation of protein biomarkers and targets. SISCAPA assays combine the precision of MRM mass spectrometry with the power of affinity enrichment to deliver a superior alternative to conventional immunoassays for protein quantitation. The SISCAPA workflow is highly automated and exploits familiar LC-MS/MS platforms widely used for drug and metabolite quantitation. At SAT we believe quantitation of proteins in biologic samples provides an actionable measure of the state of health, disease and treatment. We provide services and products for sequence-specific protein quantitation and robust generation of data in an automated, multiplexed and high throughput manner. Analysis is carried out using a generic workflow, allowing for validation and industrialization of processes for such applications as biomarker validation, protein bioanalysis, pathway research for therapeutic development and monitoring and for use in laboratory-developed tests. SISCAPA assays enable multiplexed quantitation of proteins over many orders of magnitude dynamic range. The generic, automated workflow ensures robust results with high throughput and precision. SISCAPA services include complete Assay Reagent Development or specialized Assay Implementation to maximize your up-time and help you quantitate proteins with unmatched precision. Our pipeline has generated reagents for SISCAPA quantitation of more than 250 different proteins to date, providing an unparalleled experience base.

Sound Biologics creates innovative technology to better serve patients through the development of treatments for cancer. We aspire to discover and progress therapies that will impact human health and reduce the cost of biotherapeutics.

Syntrix has pioneered the development of new therapies for over 10 years. As a clinical-stage company, we are tackling some of medicine’s most high-value diseases. One thing has remained unchanged however, our shared commitment to improving the lives of patients.

Located in Redmond WA, founded in 2014, Systimmune Inc. is a bio-pharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and tri-specific antibodies, as well as antibody-drug conjugates (ADC's). Our objective is to create biologics that work through systematic intervention on the solid tumor micro-environment, to either directly attack the tumor and/or to activate the immune system to attack the tumor. We are a group of highly experienced immuno-oncology scientists utilizing several technology platforms to develop world class advanced antibody-based drug therapies.

VMRD was founded in 1981 by D. Scott Adams, DVM, PhD, and currently employs over 50 researchers, lab technicians and support personnel. From its site in Pullman, Washington VMRD develops and manufactures veterinary diagnostic test kits and related reagents for distribution in more than 77 countries. As a rapidly growing company, VMRD strives to preserve its family focused culture and core values of integrity and quality. VMRD's services division, performs specialized testing of raw materials, cells and seeds for the presence of adventitious agents to satisfy various regulatory requirements and quality assurance needs for the global serum, veterinary and pharmaceutical industries.